Last reviewed · How we verify
Benoxyl
Benoxyl is a Small molecule drug developed by Aier School of Ophthalmology, Central South University. It is currently in Phase 2 development for Acne vulgaris, Atopic dermatitis, Contact dermatitis.
Benoxyl is a brand name for Adapalene, a medication used to treat acne. It has been studied in combination with other treatments, including Dapsone and Clindamycin/benzoyl peroxide, for the treatment of acne vulgaris and other forms of acne.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Benoxyl |
|---|---|
| Sponsor | Aier School of Ophthalmology, Central South University |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Approved indications
- Acne vulgaris
- Atopic dermatitis
- Contact dermatitis
- Eruption of skin
- Granuloma annulare
- Pruritus ani
- Pruritus of genital organs
- Seborrheic dermatitis
Common side effects
Key clinical trials
- Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center (NA)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Inova Cardiogenic Shock Registry (INOVA SHOCK)
- 1% Clascoterone Cream for the Treatment Acne Vulgaris (PHASE3)
- Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System (NA)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benoxyl CI brief — competitive landscape report
- Benoxyl updates RSS · CI watch RSS
- Aier School of Ophthalmology, Central South University portfolio CI
Frequently asked questions about Benoxyl
What is Benoxyl?
What is Benoxyl used for?
Who makes Benoxyl?
What development phase is Benoxyl in?
Related
- Manufacturer: Aier School of Ophthalmology, Central South University — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Atopic dermatitis
- Indication: Drugs for Contact dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing